TCON News and Press, TRACON Pharmaceuticals Inc. From 08/17/20

3 Penny Stocks To Watch This Week Are penny stocks something you think of when you hear the words “investing strategy”? It’s something that I’m sure has crossed your mind from time to time. These low-priced stocks have a much higher risk than their blue-chip count...

TRACON Pharmaceuticals (NASDAQ: TCON )   jumps 16%  premarket in reaction to the FDA clearance of the pivotal ENVASARC protocol filed as a part of its IND application. More news on: TRACON Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

SAN DIEGO, Aug. 17, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...

TRACON Pharmaceuticals, Inc. (TCON) Q2 2020 Earnings Conference Call August 5, 2020 4:30 PM ET Company Participants Charles Theuer – President and Chief Executive Officer Scott Brown – Chief Accounting Officer Conference Call Participants Swapnil Malekar –...

SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...

Penny Stocks Are High Risk; But The Rewards Could Be Greater No matter how you cut it, penny stocks are risky. But with great risk can come great rewards. The fact of the matter is that you can consistently make money with penny stocks . It just takes a bit of skill, practice, and education...

SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform ...

SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...

Tracon Pharmaceuticals (NASDAQ: TCON ) has filed the ENVASARC study protocol with the FDA as part of its IND application. The application cross references the open envafolimab IND maintained by company's corporate partners 3D Medicines and Alphamab Oncology. More news on: TRACON Pharma...

SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...